tiprankstipranks
PharmaCyte Biotech (PMCB)
NASDAQ:PMCB
Holding PMCB?
Track your performance easily

PharmaCyte Biotech (PMCB) Stock Price & Analysis

220 Followers

PMCB Stock Chart & Stats


Financials

Annual

Ownership Overview

4.59%3.81%88.83%
Insiders
3.81% Other Institutional Investors
88.83% Public Companies and
Individual Investors

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

PMCB FAQ

What was PharmaCyte Biotech’s price range in the past 12 months?
PharmaCyte Biotech lowest stock price was $1.39 and its highest was $2.58 in the past 12 months.
    What is PharmaCyte Biotech’s market cap?
    Currently, no data Available
    When is PharmaCyte Biotech’s upcoming earnings report date?
    PharmaCyte Biotech’s upcoming earnings report date is Mar 16, 2022 which is 983 days ago.
      How were PharmaCyte Biotech’s earnings last quarter?
      PharmaCyte Biotech released its earnings results on Dec 15, 2021. The company reported -$0.06 earnings per share for the quarter, the consensus estimate of -$0.06 by $0.
        Is PharmaCyte Biotech overvalued?
        According to Wall Street analysts PharmaCyte Biotech’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does PharmaCyte Biotech pay dividends?
          PharmaCyte Biotech does not currently pay dividends.
          What is PharmaCyte Biotech’s EPS estimate?
          PharmaCyte Biotech’s EPS estimate is -$0.05.
            How many shares outstanding does PharmaCyte Biotech have?
            PharmaCyte Biotech has 7,679,045 shares outstanding.
              What happened to PharmaCyte Biotech’s price movement after its last earnings report?
              PharmaCyte Biotech reported an EPS of -$0.06 in its last earnings report, expectations of -$0.06. Following the earnings report the stock price went down -0.481%.
                Which hedge fund is a major shareholder of PharmaCyte Biotech?
                Among the largest hedge funds holding PharmaCyte Biotech’s share is Carolina Wealth Advisors, LLC. It holds PharmaCyte Biotech’s shares valued at 3.
                  ---

                  PharmaCyte Biotech Stock Smart Score

                  10
                  Unlock Smart Score
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10

                  Technicals

                  SMA
                  Negative
                  20 days / 200 days
                  Momentum
                  -16.66%
                  12-Months-Change

                  Fundamentals

                  Return on Equity
                  47.88%
                  Trailing 12-Months
                  Asset Growth
                  -12.13%
                  Trailing 12-Months

                  Company Description

                  PharmaCyte Biotech

                  PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Laguna Hills, CA.
                  ---
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  CytoDyn
                  Organovo Holdings
                  Plus Therapeutics
                  Inovio Pharmaceuticals
                  Popular Stocks
                  ---
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis